NASDAQ:NRIX 8 December 2025 - 8 June 2026

Nurix Therapeutics shares surged in premarket trading Monday after Roche said it will pay $700 million upfront for development and commercialization rights to bexobrutideg, Nurix’s experimental drug for blood cancers and immune diseases. The stock, listed on Nasdaq, traded at $17.62 at 8:00 a.m. ET, up 20.4% from Friday’s close.

Nurix Therapeutics, Inc. is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase degrader bexobrutideg in blood cancers at the American Society of Hematology Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3